Order Code LABBAQD BCR/ABL1, Qualitative, Diagnostic Assay, Varies
Additional Codes
Mayo Test ID: BADX
Reporting Name
BCR/ABL1, RNA-Qual, DiagnosticUseful For
Diagnostic workup of patients with a high probability of BCR::ABL1-positive hematopoietic neoplasms, predominantly chronic myeloid leukemia and acute lymphoblastic leukemia
Specimen Type
VariesOrdering Guidance
This test is only qualitative and should not be used for routine monitoring (ie, quantitative messenger RNA [mRNA] level).
Monitoring of most patients with chronic myeloid leukemia should be performed using BCRAB / BCR/ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.
Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.
Additional testing options are available. For ordering guidance see BCR/ABL1 Ordering Guide for Blood and Bone Marrow
Shipping Instructions
1. Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive with 3 days of collection.
2. Collect and package specimens as close to shipping time as possible.
Necessary Information
Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR::ABL1-positive neoplasm is required.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 10 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.
Specimen Type: Bone marrow
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Specimen Minimum Volume
Peripheral blood: 8 mL; Bone marrow: 2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Refrigerated (preferred) | 5 days | PURPLE OR PINK TOP/EDTA |
Ambient | 72 hours | PURPLE OR PINK TOP/EDTA |
Reject Due To
Gross hemolysis | Reject |
Moderately to severely clotted | Reject |
Reference Values
A qualitative result is provided that indicates the presence or absence of BCR::ABL1 messenger RNA. When positive, the fusion variant is also reported.
Performing Laboratory
Mayo Clinic Laboratories in RochesterDay(s) Performed
Monday through Saturday
Method Name
Reverse Transcription Polymerase Chain Reaction (RT-PCR) Multiplex PCR
CPT Code Information
81206
81207
81208
81479 (if appropriate for government payers)
Testing Algorithm
For more information see:
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Special Instructions
Method Description
Total RNA is extracted from the patient's blood or bone marrow at the time of diagnosis and messenger RNA (mRNA) is reverse transcribed into complementary DNA (cDNA). The cDNA is then subjected to polymerase chain reaction (PCR) using 4 separate multiplex reactions. A qualitative result, which will include the relative ratio of target translocation mRNA to control GUSB gene mRNA, will be provided. Although this method employs a quantitative PCR platform, the results can be used to evaluate the relative expression levels of the translocation mRNA relative to control mRNA, thus, providing an improved measure of RNA quality in the assay. Reporting of results will be qualitative; either BCR::ABL1 mRNA positive/detected (with transcript type) or negative/not detected.(Unpublished Mayo method)
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.